Skip to main content

Advertisement

Table 4 A summary of the meta-analysis for the improvement of neurological impairment

From: Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials

AADN 0.54(0.33, 0.75) I2 = 13.4% P = 0.32 0.51(− 0.02, 1.03) I2 = 79.8% P = 0.007 1.01(0.04, 1.98) I2 = 85.2% P = 0.009 0.64(0.44, 0.84) I2 = 87.2% P = 0.000 0.77(0.43, 1.11) I2 = 0% P = 0.60 0.79(0.44,1.14) 0.53(0.01, 1.04) 0.83 (0.51, 1.16) I2 = 80.4% P = 0.02 1.03(0.56, 1.50) 0.41(0.15, 0.66)
− 0.71 (− 1.28,-0.13) DH − 1.01 (− 1.40,-0.62) − 0.61 (− 1.02,-0.20)  
− 0.83 (− 2.21,0.56) −0.12 (− 1.58,1.3) DS 0.31 (− 0.20, 0.81)
− 0.52 (− 1.15,0.1) 0.19 (− 0.64,1.01) 0.31 (− 1.18,1.8) DSCXQ − 0.82 (− 1.27,-0.37)
−0.59 (− 1.26,0.07) 0.12 (− 0.74,0.96) 0.24 (− 1.23,1.69) −0.07 (− 0.96,0.8) DZHS 0.84 (0.35, 1.33) 0.75 (0.24, 1.26)
−0.78 (− 2.19,0.63) −0.07 (− 1.57,1.41) 0.05 (− 1.88,1.97) −0.26 (− 1.78,1.2) −0.19 (− 1.68,1.2) DZXX 0.03 (− 0.49, 0.55)
0.22 (− 0.3,0.73) 0.92 (0.26,1.58) 1.05 (− 0.32,2.4) 0.74 (0.01,1.47) 0.81 (0.05,1.58) 1.00 (− 0.43,2.43) FFDS 0.79 (0.45,1.13) I2 = 0% P = 1 0.07 (−0.03, 0.45) 1.15 (0.58, 1.71) 0.95 (0.49, 1.41) 1.31 (−0.05,2.66) I2 = 95.7% P = 0 2.41 (1.85, 2.97) 0.44 (−0.12, 1.01)
−0.78 (− 1.47,-0.09) − 0.07 (− 0.97,0.83) 0.05 (− 1.49,1.58) −0.26 (− 1.19,0.6) −0.19 (− 1.16,0.7) 0 (− 1.57,1.57) − 1 (− 1.86,-0.13) HHHSS
− 0.67 (− 1.34,0) 0.04 (− 0.8,0.87) 0.16 (− 1.34,1.64) −0.14 (− 1.03,0.7) −0.08 (− 0.99,0.8) 0.11 (− 1.41,1.64) −0.88 (− 1.55,-0.21) 0.11 (− 0.85,1.08) SX
− 0.81 (− 1.44,− 0.18) -0.1 (− 0.89,0.69) 0.02 (− 1.44,1.47) −0.29 (− 1.14,0.5) −0.22 (− 0.99,0.5) −0.03 (− 1.29,1.23) −1.03 (− 1.7,-0.36) −0.03 (− 0.97,0.91) −0.14 (− 1,0.72) SXT − 0.20 (− 0.68,0.28) 0.79 (− 1.19,-0.39)
− 0.6 (− 1.61,0.39) 0.11 (− 0.97,1.16) 0.23 (−1.41,1.85) −0.08 (− 1.22,1.0) −0.01 (− 1.16,1.1) 0.18 (− 1.48,1.83) −0.82 (− 1.76,0.12) 0.18 (−1.05,1.39) 0.06 (− 1.06,1.18) 0.21 (− 0.87,1.28) XST1 0.24 (− 0.10,0.58)
−0.56 (− 1.22,0.09) 0.14 (− 0.59,0.88) 0.27 (− 1.22,1.75) −0.04 (− 0.92,0.8) 0.03 (− 0.85,0.9) 0.22 (−1.25,1.69) −0.78 (− 1.44,-0.12) 0.22 (− 0.74,1.17) 0.1 (− 0.77,0.97) 0.25 (− 0.5,1) 0.04 (− 0.88,0.97) XST2
−0.47 (− 1.13,0.19) 0.24 (− 0.61,1.08) 0.36 (−1.09,1.82) 0.05 (− 0.84,0.9) 0.12 (− 0.74,0.9) 0.31 (− 1.16,1.79) −0.69 (− 1.43,0.07) 0.31 (− 0.65,1.27) 0.2 (− 0.71,1.1) 0.34 (− 0.42,1.1) 0.13 (−1.01,1.28) 0.09 (− 0.78,0.96) LI 0.96 (0.51, 1.42)
−1.14 (− 1.74,-0.54) −0.43 (− 1.19,0.34) −0.31 (− 1.57,0.94) −0.61 (− 1.43,0.2) −0.55 (− 1.3,0.22) −0.36 (− 1.82,1.12) −1.35 (− 1.89,-0.81) −0.36 (− 1.27,0.56) −0.47 (− 1.28,0.33) −0.33 (− 1.08,0.42) −0.53 (− 1.59,0.52) −0.57 (− 1.36,0.21) −0.67 (− 1.42,0.08) YXDM 0.51 (0.06,0.95)
−1.25 (− 2.14,-0.37) − 0.54 (− 1.56,0.47) −0.41 (− 2.01,1.18) −0.72 (− 1.79,0.3) −0.65 (− 1.73,0.4) −0.46 (− 2.09,1.17) − 1.46 (− 2.36,-0.58) −0.47 (− 1.6,0.65) −0.58 (− 1.63,0.48) −0.43 (− 1.48,0.59) −0.64 (− 1.9,0.62) −0.68 (− 1.73,0.36) −0.77 (− 1.86,0.29) −0.11 (− 1.1,0.88) SXN
− 0.44 (− 1.45,0.57) 0.27 (− 0.84,1.37) 0.39 (− 1.16,1.94) 0.09 (− 1.06,1.2) 0.16 (− 0.98,1.2) 0.35 (− 1.32,2.02) −0.65 (− 1.58,0.27) 0.34 (− 0.89,1.57) 0.23 (− 0.9,1.36) 0.37 (− 0.73,1.48) 0.17 (− 1.14,1.48) 0.13 (− 0.99,1.24) 0.03 (− 1.1,1.17) 0.7 (− 0.22,1.62) 0.81 (− 0.45,2.08) MLN
  1. The upper right corner is the Meta-analysis results. The bottom left corner is the network Meta-analysis results. Results are the SMD and related 95% credibility interval (95% CI) in the row-defining treatment compared with the column -defining treatment. SMD higher than 0 favor the column-defining treatment, and vice versa. Significant effects are printed in bold. AADN aspirin + anticoagulants + dehydrant + neuroprotectant, DH Danhong injection + AADN, DS Danshen injection + AADN, DSCXQ Danshenchuangxiongqin injection + AADN, DZHS Dengzhanhuasu injection + AADN, DZXX Dengzhanxixin injection + AADN, FFDS Fufangdanshen injection + AADN, HHHSS Honghuahuangsesu injection + AADN, SX Shenxiong glucose injection + AADN, SXT Shuxuetong injection + AADN, XST1 Xueshuantong injection + AADN, XST2 Xuesetong injection + AADN, LI Ligustrazine injection + AADN, YXDM Yinxingdamo injection + AADN, SXN Shuxuening injection + AADN, MLN Mailuoning injection + AADN